23 May 2024
VENTURE LIFE GROUP
PLC
("Venture
Life", "VLG" or the "Group")
Exercise of Share Options
& Total Voting Rights
Venture Life Group PLC (AIM: VLG), a
leader in developing, manufacturing and commercialising products
for the international self-care market, announces that it has
issued 149,516 ordinary shares of 0.3 pence each in the capital of
the Company ("Ordinary Shares") following the exercise of share
options, subject to admission to trading on AIM.
Application has been made to the
London Stock Exchange for the 149,516 new Ordinary Shares to be
admitted to trading on AIM ("Admission") and it is expected that
Admission will become effective and trading will commence at 8.00
a.m. on 29 May 2024.
Following Admission, the total number
of Ordinary Shares in issue will be 126,647,713 and the total
number of voting rights will therefore be 126,647,713. This figure
may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure and Transparency
Rules.
For
further information, please contact:
Venture Life Group
PLC
+44 (0) 1344 578004
Jerry Randall, Chief Executive
Officer
Daniel Wells, Chief Financial
Officer
Cavendish Capital Markets Limited (Nomad and
Broker)
+44 (0) 20
7720 0500
Stephen Keys/Camilla Hume (Corporate
Finance)
Michael Johnson
(Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international
consumer self-care company focused on developing, manufacturing and
commercialising products for the global self-care market. With
operations in the UK, Italy, and Sweden, the Group's product
portfolio includes some key products such as the Balance Active
range in the area of women's intimate healthcare, the Earol®
product line in ENT care, the Lift and Glucogel product ranges for
energy and glucose management and hypoglycaemia, the UltraDEX and
Dentyl oral care product ranges, products for fungal infections and
proctology, and dermo-cosmetics for addressing the signs of ageing.
Its products are sold in over 90 countries worldwide.
The products, which are typically
recommended by pharmacists or healthcare practitioners, are
available primarily through pharmacies and grocery multiples. In
the UK and The Netherlands these are supplied direct by the company
to retailers, elsewhere they are supplied by the Group's
international distribution partners.
Through its two Development &
Manufacturing operations in Italy and Sweden, the Group also
provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.